TY  - JOUR
AB  - BACKGROUND: Previous studies suggest that afamin is associated with steatotic liver diseases (SLD). However, the exact role of afamin in SLD development and fibrogenesis remains unclear. Potential modifying effects of sex and glucose tolerance status have also not been examined. Therefore, we investigated the associations of afamin with steatotic liver diseases and fibrosis defined by non-invasive tests and assessed for possible effect modifications. METHODS: This study included 3080 participants from the population-based KORA F4/FF4 cohort. Cross-sectional and prospective associations (follow-up time 6.5 years) between afamin and NAFLD liver fat score (NAFLD LFS), hepatic steatosis index, fatty liver index and the fibrosis-4 index were assessed using multiple linear regression models. Models were adjusted for age, sex, body mass index, smoking status, alcohol consumption, physical activity, metabolic parameters, medication and subclinical inflammation. RESULTS: In the cross-sectional analysis, afamin concentrations were positively associated with NAFLD LFS (β = .32; 95% CI .27-.37), hepatic steatosis index (β = .33; 95% CI .26-.39) and fatty liver index (β = 1.78; 95% CI 1.47-2.08) (all p < .001), but not with fibrosis-4 index. In the prospective analysis, higher afamin levels were associated with a higher increase only in NAFLD LFS (p < .001). Cross-sectional and prospective associations between afamin and NAFLD LFS were more pronounced in men than in women (pinteraction < .001 and .022; respectively). Cross-sectional associations between afamin and NAFLD LFS were also stronger in individuals with prediabetes or diabetes compared to those with normal glucose tolerance (pinteraction < .001). CONCLUSION: Higher afamin concentrations are positively associated with NAFLD LFS with potential effect modification by sex and glucose tolerance status.
AU  - Niersmann, C.*
AU  - Zhu, A.*
AU  - Maalmi, H.*
AU  - Cai, X.
AU  - Nano, J.
AU  - Rathmann, W.*
AU  - Koenig, W.*
AU  - Takamura, T.*
AU  - Kollerits, B.*
AU  - Dieplinger, H.*
AU  - Peters, A.
AU  - Roden, M.*
AU  - Kronenberg, F.*
AU  - Thorand, B.
AU  - Herder, C.*
C1  - 75109
C2  - 57816
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
TI  - Higher afamin concentrations are associated with higher fatty liver indices: Population-based KORA F4/FF4 study.
JO  - Eur. J. Clin. Invest.
PB  - Wiley
PY  - 2025
SN  - 0014-2972
ER  - 

TY  - JOUR
AB  - Non-alcoholic fatty liver disease (NAFLD) is a most important cause of liver disease. Similar to other non-communicable diseases (NCD), such as obesity and type II diabetes mellitus, NAFLD can strongly affected by diet. Diet-related NCD and malnutrition are rising in all regions being a major cause of the global health, economic and environmental burdens. Mushrooms, important dietary components since the hunter-gathering communities, have increasingly gained momentum in biomedical research and therapeutics due to their interplay in metabolism traits. We emphasize here the beneficial effects of mushroom-enriched diets on the homeostasis of lipid and sugar metabolism, including their modulation, but also interfering with insulin metabolism, gut microbiota, inflammation, oxidative stress and autophagy. In this review, we describe the cellular and molecular mechanisms at the gut-liver axis and the liver-white adipose tissue (WAT) axis, that plausibly cause such positive modulation, and discuss the potential of mushroom-enriched diets to prevent or ameliorate NAFLD and related NCD, also within the shift needed toward healthy sustainable diets.
AU  - Fontes, A.
AU  - Ramalho-Santos, J.*
AU  - Zischka, H.
AU  - Azul, A.M.*
C1  - 62906
C2  - 51162
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
TI  - Mushrooms on the plate: Trends towards NAFLD treatment, health improvement and sustainable diets.
JO  - Eur. J. Clin. Invest.
PB  - Wiley
PY  - 2021
SN  - 0014-2972
ER  - 

TY  - JOUR
AB  - Sars-CoV-2 positive rates showed delays of about 20 days to proportional counts of positive deaths, worldwide. Using German data for the period 2/24/20 to 1/19/2021, the association of positive deaths with lagged positive rates was updated with focus on temporal homogeneity. A temporal clustering of the association between positive deaths and lagged positive rate was observed. This finding indicates unknown biological or epidemiological determinants of the pandemic and/or highlights deficits in Sars-CoV-2 metrics and statistics.
AU  - Scherb, H.
C1  - 61209
C2  - 50098
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
TI  - Sars-CoV-2 in Germany: Association between deaths and positive rate.
JO  - Eur. J. Clin. Invest.
VL  - 51
IS  - 4
PB  - Wiley
PY  - 2021
SN  - 0014-2972
ER  - 

TY  - JOUR
AB  - BACKGROUND: Fatty liver disease (FLD), primarily nonalcoholic fatty liver disease (NAFLD), is the most common liver disorder that affects a quarter of the global population. NAFLD is a spectrum of disease ranging from simple steatosis to nonalcoholic steatohepatitis, which is associated with increased risk of developing liver cancer. Given that the pathogenic mechanisms of fatty liver remain largely elusive, it is important to further investigate potential underlying mechanisms including epigenetic modifications. Here, we performed a systematic review of human epigenetic studies on FLD presence. METHODS: Five bibliographic databases were screened until 28 August 2020. We included cross-sectional, case-control and cohort studies in humans that examined the association of epigenetic modifications including global, candidate or epigenome-wide methylation of DNA, noncoding RNAs and histone modifications with FLD. RESULTS: In total 36 articles, based on 33 unique studies, consisting of 12 112 participants met the inclusion criteria. Among these, two recent epigenome-wide association studies conducted among large population-based cohorts have reported the association between cg06690548 (SLC7A11) and FLD. Moreover, several studies have demonstrated the association between microRNAs (miRNAs) and FLD, in which miR-122, miR-34a and miR-192 were recognized as the most relevant miRNAs as biomarkers for FLD. We did not find any studies examining histone modifications in relation to FLD. CONCLUSIONS: Cumulative evidence suggests a link between epigenetic mechanisms, specifically DNA methylation and miRNAs, and FLD. Further efforts should investigate the molecular pathways by which these epigenetic markers may regulate FLD and also the potential role of histone modifications in FLD.
AU  - Zhang, X.*
AU  - Asllanaj, E.*
AU  - Amiri, M.*
AU  - Portilla-Fernandez, E.*
AU  - Bramer, W.M.*
AU  - Nano, J.
AU  - Voortman, T.*
AU  - Pan, Q.*
AU  - Ghanbari, M.*
C1  - 60969
C2  - 49646
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
TI  - Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.
JO  - Eur. J. Clin. Invest.
PB  - Wiley
PY  - 2020
SN  - 0014-2972
ER  - 

TY  - JOUR
AU  - Zischka, H.
AU  - Schmitt, S.*
C1  - 56110
C2  - 46832
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 24-24
TI  - Mitochondria are indispensable for liver cancer cell proliferation.
JO  - Eur. J. Clin. Invest.
VL  - 49
PB  - Wiley
PY  - 2019
SN  - 0014-2972
ER  - 

TY  - JOUR
AU  - Degano, I.*
AU  - Kai, S.H.Y.*
AU  - Kirchberger, I.
AU  - Farmakis, D.*
AU  - Tavazzi, L.*
AU  - Marrugat, J.*
AU  - Ferrieres, J.*
C1  - 53936
C2  - 45107
CY  - Po Box 211, 1000 Ae Amsterdam, Netherlands
SP  - 135-136
TI  - In-hospital acute coronary syndrome management in Europe: Efficacy-proven pharmacological treatment trends 2000-2010, and its impact on vital status at discharge.
JO  - Eur. J. Clin. Invest.
VL  - 48
PB  - Elsevier Science Bv
PY  - 2018
SN  - 0014-2972
ER  - 

TY  - JOUR
AU  - Simoes, I.*
AU  - Karkucinska-Wieckowska, A.*
AU  - Schmitt, S.*
AU  - Ejmot, M.*
AU  - Pronicki, M.*
AU  - Zischka, H.
AU  - Oliveira, P.J.*
AU  - Wieckowski, M.R.*
C1  - 53939
C2  - 45106
CY  - Po Box 211, 1000 Ae Amsterdam, Netherlands
SP  - 52-52
TI  - Effects of Western diet on liver mitochondrial function in the context of nonalcoholic fatty liver disease.
JO  - Eur. J. Clin. Invest.
VL  - 48
PB  - Elsevier Science Bv
PY  - 2018
SN  - 0014-2972
ER  - 

TY  - JOUR
AU  - Zischka, H.
C1  - 53938
C2  - 45116
CY  - Po Box 211, 1000 Ae Amsterdam, Netherlands
SP  - 31-31
TI  - Mitochondrial adaptation in steatosis.
JO  - Eur. J. Clin. Invest.
VL  - 48
PB  - Elsevier Science Bv
PY  - 2018
SN  - 0014-2972
ER  - 

TY  - JOUR
AU  - Zischka, H.
C1  - 52086
C2  - 43714
CY  - Hoboken
SP  - 17-17
TI  - Mitochondrial toxicology: Rescuing mitochondria in Wilson disease avoids acute liver failure.
JO  - Eur. J. Clin. Invest.
VL  - 47
PB  - Wiley
PY  - 2017
SN  - 0014-2972
ER  - 

TY  - JOUR
AU  - Zischka, H.
C1  - 48675
C2  - 41273
CY  - Hoboken
SP  - 62
TI  - Rescuing mitochondria in Wilson disease avoids acute liver failure.
JO  - Eur. J. Clin. Invest.
VL  - 46
PB  - Wiley-blackwell
PY  - 2016
SN  - 0014-2972
ER  - 

TY  - JOUR
AU  - Dullaart, R.P.*
AU  - Al-Daghri, N.M.*
AU  - Ashina, M.*
AU  - Bouzas-Mosquera, A.*
AU  - Brunetti, N.D.*
AU  - Buechler, C.*
AU  - Chen, H.S.*
AU  - Corrales, J.J.*
AU  - D'Archivio, M.*
AU  - Cas, A.D.*
AU  - Pino, G.G.*
AU  - Gómez-Abril, S.A.*
AU  - Győri, D.*
AU  - Haslacher, H.*
AU  - Herder, C.
AU  - Kerstens, M.N.*
AU  - Koutsilieris, M.*
AU  - Lombardi, C.*
AU  - Lupattelli, G.*
AU  - Mócsai, A.*
AU  - Msaouel, P.*
AU  - Orfao, A.*
AU  - Ormazabal, P.*
AU  - Pacher, R.*
AU  - Perkmann, T.*
AU  - Peteiro, J.*
AU  - Plischke, M.*
AU  - Reynaert, N.L.*
AU  - Ricci, M.A.*
AU  - Robles, N.R.*
AU  - Rocha, M.*
AU  - Rutten, E.P.*
AU  - Sabico, S.*
AU  - Santamaria, F.*
AU  - Santoro, F.*
AU  - Schmid, A.*
AU  - Schmidt, M.*
AU  - Schytz, H.W.*
AU  - Shyu, K.G.*
AU  - Tada, H.*
AU  - Thorand, B.
AU  - Valerio, G.*
AU  - Vesely, D.L.*
AU  - Wu, T.E.*
AU  - Yamagishi, M.*
AU  - Yeh, Y.T.*
C1  - 32516
C2  - 35094
CY  - Hoboken
SP  - 1010-1023
TI  - Research update for articles published in EJCI in 2012.
JO  - Eur. J. Clin. Invest.
VL  - 44
IS  - 10
PB  - Wiley-Blackwell
PY  - 2014
SN  - 0014-2972
ER  - 

TY  - JOUR
AB  - Background  We tested the hypothesis that high TGF-β1 content in atherosclerotic plaques and high TGF-β1 serum levels are associated with lower risk of coronary events in two independent prospective studies. Materials and methods  In the prospective Athero-Express biobank study, total TGF-β1 plaque levels were measured in 632 atherosclerotic lesions from patients who underwent carotid endarterectomy. In a population-based case-cohort study within the Monitoring of trends and determinants in cardiovascular disease (MONICA)/Cooperative Health Research in the Region of Augsburg (KORA) Augsburg studies, baseline total TGF-β1 serum levels were measured in 333 individuals with and 1728 without incident coronary events. Results  Patients with TGF-β1 content in their plaques above the study median did not have a lower risk of coronary events than patients with lower TGF-β1 levels [adjusted HR (95% CI) 1·46 (0·83-2·53); P = 0·16; mean follow-up 2·6 ± 0·7 years] in the Athero-Express biobank study. Cox proportional hazard models adjusting for age, sex, body mass index, metabolic factors, lifestyle factors and survey did not reveal a significant association between TGF-β1 serum levels and incident coronary events [HR (95% CI) for increasing TGF-β1 tertiles 1·0, 1·22 (0·88-1·68), 1·13 (0·82-1·57); P = 0·47; mean follow-up: 10·8 ± 4·6 years] in the MONICA/KORA Augsburg studies. Conclusion  Our results indicate that high TGF-β1 content in human atherosclerotic plaques and high serum levels of TGF-β1 are not associated with reduced risk of coronary events.
AU  - Herder, C.*
AU  - Peeters, W.*
AU  - Zierer, A.
AU  - de Kleijn, D.P.*
AU  - Moll, F.L.*
AU  - Karakas, M.*
AU  - Roden, M.*
AU  - Meisinger, C.
AU  - Thorand, B.
AU  - Pasterkamp, G.*
AU  - Koenig, W.*
C1  - 7233
C2  - 29571
SP  - 329-337
TI  - TGF-β1 content in atherosclerotic plaques, TGF-β1 serum concentrations and incident coronary events.
JO  - Eur. J. Clin. Invest.
VL  - 42
IS  - 3
PB  - Wiley-Blackwell
PY  - 2012
SN  - 0014-2972
ER  -